CytRx Corp. (CYTR) Awarded Positive Opinion from European Medicines Agency for Leukemia Drug Candidate
CytRx Corp. is a biopharmaceutical research and development company focused on the development of high-value human therapeutics. Its current development pipeline includes programs in clinical development for cancer indications, including its lead drug candidate tamibarotene, for the treatment of acute promyelocytic leukemia (APL). The company today announced that tamibarotene has received an official positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency. The opinion now sits before the European Union (EU) commission for final approval and publication in the community register. The company has already secured Orphan Drug Designation for APL and Fast Track…